Development Technologies Corp. (DVTC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $273M is the value of all shares combined. Beta 3.97: the stock has moved about 297% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDevelopment Technologies Corp. (DVTC) trades at $5.01. Development Technologies Corp. (DVTC), operating as Pegasus Pharmaceuticals Inc., focuses on manufacturing and providing advanced ECG systems. Market cap: $273M, Sector: Financial services.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for DVTC: DVTC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DVTC against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
DVTC: the 2 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Development Technologies Corp. (DVTC) Financial Services Profile
Development Technologies Corp., through its Pegasus Pharmaceuticals Inc. subsidiary, manufactures and distributes the HeartVue 6S System, a non-invasive ECG technology used in various medical settings. With a market capitalization of $273M and a high beta of 3.97, the company operates within the financial services sector as a shell company.
What Is the Investment Thesis for DVTC?
Development Technologies Corp., with a market cap of $273M and a beta of 3.97, presents a speculative investment opportunity tied to the success of its HeartVue 6S System. The company's focus on non-invasive cardiac screening caters to a growing demand for early and accurate diagnostics. Growth catalysts include potential partnerships with major hospital networks and expansion into international markets. However, the company's status as an OTC-listed shell company introduces significant risks, including limited liquidity and disclosure. Investors should carefully assess the market adoption of the HeartVue 6S System and the company's ability to navigate the regulatory landscape for medical devices.
Based on FMP financials and quantitative analysis
DVTC Key Highlights
Market capitalization of $273M, indicating a small-cap company.
- High beta of 3.97, suggesting high volatility compared to the overall market.
- Operates as Pegasus Pharmaceuticals Inc., focusing on the manufacturing and distribution of the HeartVue 6S System.
- Serves a diverse range of healthcare providers, including hospitals, clinics, and emergency medical facilities.
- Founded in 1995, indicating a history of over 25 years in the medical device industry.
Who Are DVTC's Competitors?
DVTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AMRR American Metals Recovery and Recycling Inc. | $1.30 | 0.00% | $251M | — |
| BNZIF Fideicomiso Irrevocable F/2061 FHipo | $0.49 | 0.00% | $284M | — |
| CINV Crucial Innovations Corp. | $4.55 | 0.00% | $339M | — |
| FZRO FlashZero Corp. | $2.00 | 0.00% | $346M | — |
| TDAC Translational Development Acquisition Corp. | $10.90 | -0.09% | $268M | 465-pillar |
| RFAI RF Acquisition Corp II | $32.00 | -0.03% | $267M | 485-pillar |
| OACC Oaktree Acquisition Corp. III Life Sciences | $10.82 | +0.46% | $266M | 505-pillar |
| CEPV Cantor Equity Partners V, Inc. | $10.41 | +0.19% | $266M | 485-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DVTC's Key Strengths?
Specialized ECG technology with the HeartVue 6S System.
- Established presence in the medical device industry.
- Serves a diverse range of healthcare providers.
- Focus on non-invasive cardiac screening.
What Are DVTC's Weaknesses?
Small market capitalization of $273M.
- High beta of 3.97, indicating high volatility.
- Limited financial resources compared to larger competitors.
- Dependence on a single product, the HeartVue 6S System.
What Could Drive DVTC Stock Higher?
DVTC catalyst: Potential partnerships with major hospital networks to integrate the HeartVue 6S System into their diagnostic protocols.
- Expansion into international markets, particularly in regions with growing healthcare infrastructure.
- Continued marketing and sales efforts to increase product awareness and adoption.
- Research and development of next-generation ECG technology to enhance product features and performance.
What Are the Key Risks for DVTC?
Limited liquidity and trading volume due to OTC listing.
- Dependence on a single product, the HeartVue 6S System.
- Competition from established medical device manufacturers.
- Stringent regulatory requirements for medical devices.
- Product liability claims related to the HeartVue 6S System.
What Are the Growth Opportunities for DVTC?
- Expansion into International Markets: Development Technologies Corp. can pursue growth by expanding the distribution of its HeartVue 6S System into international markets, particularly in regions with growing healthcare infrastructure and increasing prevalence of heart diseases. This expansion could involve establishing partnerships with local distributors or setting up regional offices to market and sell the product.
- Strategic Partnerships with Hospital Networks: Collaborating with major hospital networks to integrate the HeartVue 6S System into their diagnostic protocols can drive significant sales and market penetration. These partnerships can provide access to a large patient base and enhance the credibility of the product. Securing contracts with leading hospital groups can establish a recurring revenue stream and strengthen the company's market position.
- Development of Next-Generation ECG Technology: Investing in research and development to create next-generation ECG technology can provide a competitive edge and attract new customers. This could involve developing more advanced features, improving the accuracy and speed of diagnosis, or integrating the system with other medical devices. Innovation in ECG technology can open up new market segments and increase the company's revenue potential.
- Targeting Telemedicine and Remote Monitoring: With the rise of telemedicine and remote patient monitoring, Development Technologies Corp. can adapt its HeartVue 6S System for remote use. This could involve developing a portable version of the device or integrating it with telemedicine platforms. Targeting the telemedicine market can expand the company's reach and cater to the growing demand for remote healthcare solutions.
- Focusing on Preventative Care and Wellness Programs: Promoting the HeartVue 6S System for preventative care and wellness programs can tap into a new market segment focused on early detection and prevention of heart diseases. This could involve partnering with fitness facilities, sports teams, and corporate wellness programs to offer cardiac screening services. Emphasizing the benefits of early detection can drive adoption and increase sales.
What Are DVTC's Competitive Advantages?
- Specialized ECG technology with the HeartVue 6S System.
- Established presence in the medical device industry since 1995.
- Relationships with healthcare providers and facilities.
What Does DVTC Do?
Founded in 1995 and headquartered in Palm Beach Gardens, Florida, Development Technologies Corp., operating as Pegasus Pharmaceuticals Inc., specializes in the development, manufacturing, and distribution of advanced ECG systems. The company's primary product, the HeartVue 6S System, is designed for the non-invasive screening of heart pathologies. This system is utilized by a diverse range of healthcare providers, including cardiologists, general practitioners, physicians, intensive care units, hospitals, emergency rooms, clinics, fitness facilities, sports teams, and other emergency medical facilities. The HeartVue 6S System aims to provide a screening tool for diagnosing heart and other cardiac diseases. The company focuses on serving a broad spectrum of medical and emergency facilities, indicating a strategy to penetrate various segments within the healthcare market. As a shell company in the financial services sector, Development Technologies Corp.'s value is closely tied to the performance and market acceptance of its Pegasus Pharmaceuticals subsidiary and its HeartVue 6S System. The company's business model centers around the sales and distribution of this specialized medical device, targeting healthcare providers and facilities seeking advanced cardiac screening solutions.
What Products and Services Does DVTC Offer?
- Manufactures the HeartVue 6S System, an advanced ECG system.
- Provides non-invasive screening tools for heart pathologies.
- Serves cardiologists and general practitioners.
- Caters to hospitals and emergency rooms.
- Offers solutions for intensive care units and clinics.
- Supplies equipment to fitness facilities and sports teams.
- Provides cardiac screening tools for emergency medical facilities.
How Does DVTC Make Money?
- Manufacturing and selling the HeartVue 6S System.
- Distribution through direct sales and partnerships.
- Providing maintenance and support services for the ECG systems.
What Industry Does DVTC Operate In?
Development Technologies Corp. operates within the financial services sector as a shell company, with its primary business being the manufacturing and distribution of the HeartVue 6S System through its Pegasus Pharmaceuticals Inc. subsidiary. The medical device industry is characterized by technological advancements and stringent regulatory requirements. The company competes with established medical device manufacturers and emerging technology providers. The market for cardiac screening devices is driven by the increasing prevalence of heart diseases and the demand for non-invasive diagnostic solutions.
Who Are DVTC's Key Customers?
- Cardiologists and general practitioners.
- Hospitals and emergency rooms.
- Intensive care units and clinics.
- Fitness facilities and sports teams.
- Emergency medical facilities.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 44 |
| 2026-08-27 | 44 |
| 2026-08-31 | 44 |
| 2026-09-04 | 44 |
| 2026-09-08 | 44 |
| 2026-09-11 | 44 |
What changed?
The score has stayed at 44.
Over the same 19 days the stock moved +0.2%.
Company Profile
Development Technologies Corp. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Palm Beach Gardens, US. The company is led by CEO Daniel Kesonen. DVTC has traded publicly since 1997.
DVTC Financials
Bull Case vs Bear Case
Bull Case
- Specialized ECG technology with the HeartVue 6S System.
- Established presence in the medical device industry.
- Serves a diverse range of healthcare providers.
- Focus on non-invasive cardiac screening.
Bear Case
- Small market capitalization of $273M.
- High beta of 3.97, indicating high volatility.
- Limited financial resources compared to larger competitors.
- Dependence on a single product, the HeartVue 6S System.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DVTC Latest News
No recent news available for DVTC.
DVTC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DVTC.
Price Targets
Wall Street price target analysis for DVTC.
DVTC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DVTC; grades run from A+ (80-100) to F (below 30).
Leadership: Daniel Kesonen
CEO
Daniel Kesonen serves as the CEO of Development Technologies Corp. His background includes experience in the pharmaceutical and medical device industries. He has held various leadership positions in sales, marketing, and product development. Kesonen's expertise lies in commercializing innovative healthcare solutions and driving market adoption. He holds a degree in business administration and has completed executive education programs in leadership and strategy.
Track Record: Under Daniel Kesonen's leadership, Development Technologies Corp. has focused on expanding the market reach of the HeartVue 6S System. He has overseen the development of strategic partnerships with healthcare providers and the implementation of marketing initiatives to increase product awareness. His tenure has been marked by efforts to enhance the company's financial performance and strengthen its position in the cardiac screening market.
DVTC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Development Technologies Corp. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to regular reporting requirements with the SEC. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited liquidity and trading volume.
- Lack of regulatory oversight and disclosure.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Difficulty in obtaining reliable information about the company.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the market potential of the HeartVue 6S System.
- Research the company's regulatory compliance and legal standing.
- Determine the company's ownership structure and related-party transactions.
- Analyze the company's competitive landscape and market share.
- Understand the risks associated with investing in OTC stocks.
- Established presence in the medical device industry since 1995.
- Focus on a specific product, the HeartVue 6S System.
- Serves a diverse range of healthcare providers.
- CEO with experience in the pharmaceutical and medical device industries.
Development Technologies Corp. Financial Services Stock: Key Questions Answered
Is DVTC a good stock?
Stock Expert AI does not rate DVTC buy, sell or hold. Development Technologies Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about DVTC stock?
Given its OTC listing and small market capitalization, analyst coverage is likely limited. Investors should conduct their own due diligence and carefully assess the company's financial performance, market potential, and risk factors. Key valuation metrics to consider include revenue growth, gross margin, and cash flow.
What are the key factors to evaluate for DVTC?
Evaluate DVTC on fundamentals, analyst consensus, and risk factors. The company's focus on non-invasive cardiac screening caters to a growing demand for early and accurate diagnostics. Not financial advice.
How frequently does DVTC data refresh on this page?
DVTC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven DVTC's recent stock price performance?
Development Technologies Corp. (DVTC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized ECG technology with the HeartVue 6S System. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DVTC overvalued or undervalued right now?
Development Technologies Corp. (DVTC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of DVTC?
Yes, most major brokerages offer fractional shares of Development Technologies Corp. (DVTC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track DVTC's earnings and financial reports?
Development Technologies Corp. (DVTC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for DVTC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.